1.Research progress of small peptidomimetics.
Acta Pharmaceutica Sinica 2015;50(8):931-944
The study of peptide drugs has been an important direction in research and development of new drugs. However, lots of natural macromolecular peptides are limited in clinical use by their metabolic instability and low bioavailability. In recent years, the active small peptidomimetics open up a new hotspot of peptide drug development with the characteristics of low molecular weight, high bioactivity and structural modification. Many peptidomimetics are on the market or on the clinical study. This paper elaborated the small peptidomimetics approved by American Food and Drug Administration (FDA) from 2005 to 2014, and reviewed their researching status with source, synthetic method, chemical structure, marketing time, indication, clinical efficacy and safety. Research prospects in this field were discussed.
Biomedical Research
;
trends
;
Peptidomimetics
;
United States
;
United States Food and Drug Administration
2.Recent progress in development of antibiotics against Gram-negative bacteria.
Acta Pharmaceutica Sinica 2013;48(7):993-1004
Multidrug-resistant (MDR) bacterial infections, especially those caused by Gram-negative pathogens, have emerged to be one of the world's greatest health threats. However, not only have recent decades shown a steady decline in the number of approved antimicrobial agents but a disappointing discovery also void. The development of novel antibiotics to treat MDR Gram-negative bacteria has been stagnated over the last half century. Though few compounds have shown activities in vitro, in animal models or even in clinical studies, the global antibiotic pipeline is not encouraging. There are a plethora of unexpected challenges that may arise and cannot always be solved to cause promising drugs to fail. This review intends to summarize recent research and development activities to meet the inevitable challenge in restricting the proliferation of MDR Gram-negative bacteria, with focus on compounds that have entered into clinical development stage. In addition to new analogues of existing antibiotic molecules, attention is also directed to alternative strategies to develop antibacterial agents with novel mechanisms of action.
Aminoglycosides
;
pharmacology
;
therapeutic use
;
Animals
;
Anti-Bacterial Agents
;
pharmacology
;
therapeutic use
;
Antibodies, Monoclonal
;
pharmacology
;
therapeutic use
;
Drug Discovery
;
Drug Resistance, Multiple, Bacterial
;
Enzyme Inhibitors
;
pharmacology
;
therapeutic use
;
Ferrous Compounds
;
pharmacology
;
therapeutic use
;
Gram-Negative Bacteria
;
drug effects
;
Gram-Negative Bacterial Infections
;
drug therapy
;
Humans
;
Peptides
;
pharmacology
;
therapeutic use
;
Peptidomimetics
;
pharmacology
;
therapeutic use
;
Tetracyclines
;
pharmacology
;
therapeutic use
;
beta-Lactamase Inhibitors
;
beta-Lactams
;
pharmacology
;
therapeutic use